Macular profile of eyes developing macular holes in cases of central retinal vein occlusion treated with Bevacizumab

Authors

  • Anadi Khatri Vitreo-Retinal Surgeon, Department of Vitreo-Retina Disease and Surgery, Birat Eye Hospital, Biratnagar, Nepal https://orcid.org/0000-0002-0444-224X
  • Pratap Karki Vitreo-Retinal Surgeon, BP Koirala Lions Centre for Ophthalmic Studies, Institute of Medicine, Tribhuvan University, Nepal
  • Sagun Narayan Joshi Vitreo-Retinal Surgeon, BP Koirala Lions Centre for Ophthalmic Studies, Institute of Medicine, Tribhuvan University, Nepal https://orcid.org/0000-0002-5857-2218
  • Bal Kumar Khatri Senior Consultant, Birat Eye Hospital, Biratnagar, Nepal
  • Muna Kharel Resident, Department of Ophthalmology, Nepalese Army Institute of Health Sciences, Kathmandu, Nepal https://orcid.org/0000-0001-9163-0267
  • Amrit Banstola Ophthalmologist, Lumbini Eye Institute and Research Centre, Lumbini, Nepal
  • Saurav Man Shrestha Ophthalmologist, Lumbini Eye Institute and Research Centre, Lumbini, Nepal

DOI:

https://doi.org/10.3126/jkmc.v9i1.33516

Keywords:

Bevacizumabm, Central retinal vein occlusion, Cystoid macular edema, Macular hole, Vitreous detachment, Vireo-macular traction

Abstract

Background: Anti-vascular endothelial growth factors are commonly used for treatment for central retinal vein occlusion. There have been numerous reports regarding both the benefits and disadvantages of its use. Recently, a rather surprising complication- development of macular holes have started emerging.

Objectives: The purpose of this study was to evaluate if the patient's profile, baseline optical coherence tomography parameters, status of the vitreous and subsequent response pose a risk for macular hole formation in cases of central retinal vein occlusion central retinal vein occlusion following treatment with bevacizumab. 

Methodology: This prospective exploratory analytical study was conducted at a tertiary eye care center of Nepal and evaluated 97 eyes with central retinal vein occlusion undergoing treatment with bevacizumab.

Results: Full Thickness Macular Hole  developed in eight (8.24%) of the central retinal vein occlusion eyes treated with bevacizumab. Elderly age and eyes with cystoid edema at baseline were found to have greater risk of developing macular hole following treatment (OR: 8.97 , p<0.05). Twelve eyes (12.3%) of the eyes treated developed vitreoretinal interface anomalies and were the result of dramatic decrease in central macular thickness . All of them had cystoid macular edema at baseline. Five of them (42%) developed full thickness macular hole.

Conclusion: Anti-vascular endothelial growth factor agents have been widely accepted as the first line of choice for treatment of macular edema secondary to central retinal vein occlusion. Cystoid macular edema, eyes of the elderly and those showing dramatic decrease in central macular thickness with the development of anomalous vitreoretinal interface are potential risk factors for full thickness macular hole.

Downloads

Download data is not yet available.
Abstract
191
PDF
177

Downloads

Published

2020-03-31

How to Cite

Khatri, A., Karki, P., Joshi, S. N., Khatri, B. K., Kharel, M., Banstola, A., & Shrestha, S. M. (2020). Macular profile of eyes developing macular holes in cases of central retinal vein occlusion treated with Bevacizumab. Journal of Kathmandu Medical College, 9(1), 13–19. https://doi.org/10.3126/jkmc.v9i1.33516

Issue

Vol. 9 No. 1 (2020)

Section

Original Research Articles

License

Copyright © Journal of Kathmandu Medical College
The ideas and opinions expressed by authors or articles summarized, quoted, or published in full text in this journal represent only the opinions of the authors and do not necessarily reflect the official policy of Journal of Kathmandu Medical College or the institute with which the author(s) is/are affiliated, unless so specified.

Authors convey all copyright ownership, including any and all rights incidental thereto, exclusively to JKMC, in the event that such work is published by JKMC. JKMC shall own the work, including 1) copyright; 2) the right to grant permission to republish the article in whole or in part, with or without fee; 3) the right to produce preprints or reprints and translate into languages other than English for sale or free distribution; and 4) the right to republish the work in a collection of articles in any other mechanical or electronic format.